Thromboembolic Disorders: Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Cardiovascular Disease
AHA Statement on Managing Pregnant Women With CVD
The American Heart Association outlined several considerations for the management of pregnant women with CVD or CVD-related conditions.
Hypertension: Beta-Blocker Pharmacokinetics
Beta-blocker pharmacokinetics comparison chart for hypertension.
Dyslipidemia Drug Indications
Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
FDA Issues Statement Regarding NSAID Use and COVID-19
The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).
ACC Issues COVID-19 Clinical Guidance for Cardiovascular Care Team
On March 6, 2020, the American College of Cardiology issued COVID-19 clinical guidance for the cardiovascular care team.
Hypertension Treatments: Oral CCBs
Oral calcium channel blockers (CCBs) for the treatment of hypertension including benzothiazepines, dihydropyridines, and diphenylalkylamines.
Effect of HCV Clearance on Cardiovascular Risks in People With HIV
In patients coinfected with HIV and HCV, eradication of HCV had no effect on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
Apabetalone Gets Breakthrough Therapy Designation for MACE Prevention
The FDA has granted Breakthrough Therapy designation to apabetalone in combination with standard of care therapy for the secondary prevention of MACE in patients with T2Dm and recent ACS.
Racial/Ethnic Disparities in Use of Low-Dose Aspirin for CVD Prevention
Lower use of low-dose aspirin for the primary prevention of cardiovascular disease (CVD) in blacks vs whites may partly account for racial discrepancies in the incidence of ischemic cardiac death.
-
Loading...
-
Loading...
Next post in Prevention
